The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Human leukocyte antigen (HLA) B44 supertype and immunotherapy outcomes in non-small cell lung cancer (NSCLC).
 
Henry Lu
No Relationships to Disclose
 
Amy Lauren Cummings
No Relationships to Disclose
 
Jonathan Wade Goldman
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Clovis Oncology; Genentech/Roche; Lilly; Trovagene; Vortex Biosciences
Speakers' Bureau - Merck
Research Funding - Abbvie; Array BioPharma; Astellas Pharma; Astex Pharmaceuticals; AstraZeneca/MedImmune; Bristol-Myers Squibb; Celgene; Clovis Oncology; Corvus Pharmaceuticals; Genentech/Roche; Lilly; Threshold Pharmaceuticals
 
Aaron Elliott Lisberg
No Relationships to Disclose
 
Siwen Hu-Lieskovan
Consulting or Advisory Role - Amgen; Genmab; Merck
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Nektar (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Plexxikon (Inst); Vaccinex (Inst)
 
Tristan Grogan
No Relationships to Disclose
 
Jaklin Gukasyan
No Relationships to Disclose
 
John Madrigal
No Relationships to Disclose
 
James M. Carroll
No Relationships to Disclose
 
Krikor Bornazyan
No Relationships to Disclose
 
Benjamin Jones
No Relationships to Disclose
 
Zorawar Singh Noor
No Relationships to Disclose
 
Jesse Meir Zaretsky
No Relationships to Disclose
 
David Elashoff
No Relationships to Disclose
 
Dennis J. Slamon
No Relationships to Disclose
 
Steven M. Dubinett
No Relationships to Disclose
 
Edward B. Garon
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst)